Precipio, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 19.3K | $482.50K | 0.00% | Added+33.1% | 2026-03-31 |
| FidelityFMR | fundamental | 2 | $55 | 0.00% | Trimmed-95.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2023-11-13 | -1.40 | -1.04 | +25.71% |
| 2023-08-11 | -2.00 | -1.80 | +10.00% |
| 2023-05-12 | -2.60 | -2.60 | — |
| 2023-03-30 | -2.80 | -2.00 | +28.57% |
| 2022-11-10 | -0.80 | -2.80 | -250.00% |
| 2022-08-11 | -1.00 | -1.80 | -80.00% |
| 2022-05-11 | -1.00 | -4.00 | -300.00% |
| 2022-03-30 | -1.40 | -1.80 | -28.57% |
| 2021-11-12 | -2.00 | -1.60 | +20.00% |
| 2021-08-12 | -2.00 | -2.80 | -40.00% |
| 2021-05-14 | -2.00 | -1.60 | +20.00% |
| 2020-11-13 | -4.00 | -4.20 | -5.00% |
| 2020-08-13 | -4.00 | -4.00 | — |
| 2020-05-14 | -3.60 | -12.72 | -253.28% |
| 2020-03-27 | -5.00 | -9.60 | -92.00% |
| 2019-11-13 | -7.80 | -6.20 | +20.51% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| PRPO | -26.31% | -15.02% | -0.78% | +109.16% |
| XLV | +2.97% | -4.83% | -3.44% | +12.62% |
| Alpha (stock − sector) | -29.28% | -10.19% | +2.66% | +96.53% |